BVNRY BAVARIAN NORDIC

-

BAVARIAN NORDIC Reported Earnings

Friday, November 13, 2026 · 12:00 AM ET

BAVARIAN NORDIC (BVNRY) reported earnings of $0.28 per share on revenue of $277.86 million for the . . Revenue fell 1.16% compared to the same quarter a year ago.

Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.

Earnings Whisper Grade
Power Rating
Reported Earnings
$0.28
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth-61.1 %
Reported Revenue
$277.86M
Revenue Estimate
—
Revenue Surprise
Revenue Growth-1.2 %

*Reported earnings and revenue figures shown above, and any guidance given, are preliminary and may be updated upon further review.*